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Cutaneous metastasis is an uncommon manifes-
tation of internal malignancy. The rate of cutaneous
metastasis in ovarian cancer is 3.5%, andmedian time
of survival after appearance of cutaneous metastasis
is 4 months.1 The lesions involved are often
described as flesh colored, pink, or violaceous
cutaneous or subcutaneous nodules, although re-
ports of non-nodular metastases exist.2 We report
the case of a 24-year-old woman with refractory
stage IIIB mucinous adenocarcinoma of the ovary
presenting with cutaneous metastases to her breasts
masquerading as localized scleroderma.CASE REPORT
A 24-year-old Hispanic woman presented with a
3-month history of painful, pruritic, progressive rash
localized to both breasts. Her medical history
was significant for refractory metastatic stage IIIB
mucinous adenocarcinoma of the ovary diagnosed
10 months before appearance of the rash.
Initial management included right salpingo-
oophorectomy, omentectomy, stripping of bladder
peritoneum, pelvic and para-aortic lymph node
dissection, and appendectomy. She declined adju-
vant chemotherapy and completion surgery in a
desire to preserve fertility. Five months after treat-
ment she presented with abdominal pain, bilateral
hydronephrosis, renal failure, ascites, and computed
tomography findings consistent with recurrence of
her ovarian adenocarcinoma, and 3 months later the
rash began.
She was not on chemotherapy at presentation. The
rash initially manifested near her port site on the right
chest wall and was attributed to allergic contact
dermatitis from ChloraPrep (Becton, Dickinson andthe Department of Dermatology,b University of Texas Health
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u.Company,Franklin Lakes,NJ).Over thenext2months,
the patient described enlargement and hardening of
bilateral breasts, originating on the right and spreading
to the left. Her medical history was otherwise normal.
On physical examination, bilateral breasts were
tender to palpation and exhibited diffuse dermal
induration and taut skin with erythematous and
hyperpigmented patches (Fig 1). There was no
nipple discharge, peau d’ orange, nodular infiltrates,
or axillary, cervical, or supraclavicular lymphade-
nopathy. Findings for the remainder of the full-body
skin examination were normal with the exception of
a large suprapubic abdominal mass noted on deep
palpation.
Histopathologic examination of skin from the left
breast found tumor cells and mucin resembling
primary tumor. Immunostaining for estrogen and
progesterone receptors, mammaglobulin, and gross
cystic disease fluid were negative. The patient was
discharged home to hospice care and died 4 months
after appearance of the rash.DISCUSSION
Cutaneous metastasis is an uncommon manifesta-
tion of internal malignancy. Spread of a primary tumor
to the skin typically occurs late in the course of disease
but may be the presenting sign of underlying cancer.
The overall incidence of cutaneous metastasis from
visceral neoplasia is 5.3%.Breast cancerhas thehighest
incidence of cutaneous metastasis (24%), whereas
lung, colorectal, renal, ovarian, and bladder cancers
all have rates between 3.4% and 4.0%. The most
common site for cutaneous metastases from visceral
malignancies to occur is the chest, comprising 28.4%of
the total, followed by the abdomen (20.2%), extrem-
ities (12%), neck (11%), back (11%), scalp (7%), pelvisJAAD Case Reports 2016;2:406-7.
2352-5126
 2016 by the American Academy of Dermatology, Inc. Published
by Elsevier, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
http://dx.doi.org/10.1016/j.jdcr.2016.08.010
Fig 1. Cutaneous metastases from adenocarcinoma of the ovary presenting as diffuse dermal
induration and taut skin with erythematous and hyperpigmented patches.
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as flesh-colored, pink, or violaceous cutaneous or
subcutaneous nodules, although reports of non-
nodular metastases exist.2
The most common sites of distant metastasis for
ovarian cancer are the pleura, liver, bone, lung, and
lymph nodes, whereas cutaneous metastases are
rare.3,4 In a study performed on 220 patients with
epithelial ovarian carcinoma, a rate of 3.5% for
cutaneous metastases was detected. The average
time of appearance of skin metastases after the
diagnosis of ovarian cancer was 23.4 6 12 months,
and the diameter of the skin lesions (usually nodular)
ranged between 0.5 and 3.0cm. Median survival after
diagnosis of skin metastasis from ovarian cancer was
4 months.1
The most common type of cutaneous metastatic
ovarian carcinoma is epithelial ovarian adenocarci-
noma. This carcinoma can have serous, endome-
trioid, mucinous, or clear epithelial cells, which often
manifests with nuclear atypia, mitoses, and cystic
and solid cellular arrays. Cutaneous metastatic
ovarian carcinoma most commonly presents as sol-
itary, grouped papules and or nodules on the trunk.5
Reports indicate that only 12% of cases of cutaneous
metastasis from ovarian carcinoma occur on the
limbs, with most metastatic skin lesions occurring
in skin adjacent to the primary ovarian cancer
including the abdominal wall.3,6 Cutaneous metas-
tases were found at or around abdominal wall
incisions, from laparotomy, laparoscopy, port and
catheter, or drainage scars.1Other forms of cutaneous metastatic ovarian
carcinoma include herpetiform-pattern metastatic
nodules, erythema annulare, cutaneous metastases
with calcospherites, scalp nodules, subungual
metastases, skin nodules, subcutaneous metasta-
ses, and lymphangiosis carcinomatosa of the skin.
Paraneoplastic associations of ovarian carcinoma
include acanthosis nigricans, Raynaud’s phenome-
non, scleroderma, dermatomyositis, and palmar
fasciitis with polyarthritis. Both cutaneous para-
neoplastic effects and metastatic presentations
portend a poor prognosis in ovarian carcinoma.5
Our case is one example of the many unusual
presentations of cutaneous metastatic ovarian
cancer.
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